Hydroxymethylglutaryl-CoA Reductase Inhibitors
Showing 1 - 25 of 4,513
Dyslipidemias, Hyperlipidemias, Liver Transplant Disorder Trial in Moscow (Pitavastatin, PCSK9 inhibitor)
Recruiting
- Dyslipidemias
- +5 more
- Pitavastatin
- PCSK9 inhibitor
-
Moscow, Russian FederationNational Medical Research Centre for Therapy and Preventive Medi
Sep 8, 2022
Hydroxymethylglutaryl-CoA Reductase Inhibitors, Diabetes Trial in Cairo (Atorvastatin 40 Mg Oral Tablet, Rosuvastatin 20 Mg Oral
Completed
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Diabetes Mellitus
- Atorvastatin 40 Mg Oral Tablet
- Rosuvastatin 20 Mg Oral Tablet
-
Cairo, EgyptHeart Institute
Mar 24, 2022
Cardiovascular Drugs Adverse Reaction
Recruiting
- Pharmacogenetics
- +2 more
- Oral Anticoagulant, Direct-Acting
-
Zagreb, CroatiaUHC Zagreb
Mar 23, 2022
Hyperlipidemias Trial in Boston (Evolocumab, Statins (Cardiovascular Agents))
Recruiting
- Hyperlipidemias
- Evolocumab
- Statins (Cardiovascular Agents)
-
Boston, MassachusettsBrigham and Women's Hospital
Jul 18, 2022
Preventing Levodopa Induced Dyskinesia in Parkinson's Disease
Recruiting
- Parkinson Disease
- Dyskinesia, Drug-Induced
- Intravenous Infusion
-
Portland, Oregon
- +2 more
Dec 23, 2022
Aortic Stenosis Trial in Beijing (PCSK9 inhibitor and Statin, Statin)
Recruiting
- Aortic Stenosis
- PCSK9 inhibitor and Statin
- Statin
-
Beijing, Beijing, ChinaBeijing Anzhen Hospital, Capital Medical University
Sep 4, 2021
Hypercholesterolemia Trial (Ezetimibe, atorvastatin)
Completed
- Hypercholesterolemia
- (no location specified)
Feb 7, 2022
Hypercholesterolemia Trial (Ezetimibe, Simvastatin)
Completed
- Hypercholesterolemia
- (no location specified)
Feb 7, 2022
In-stent Restenosis, Major Adverse Cardiovascular Events Trial in Beijing (PCSK9 inhibitor, Statin)
Recruiting
- In-stent Restenosis
- Major Adverse Cardiovascular Events
- PCSK9 inhibitor
- Statin
-
Beijing, Beijing, ChinaBeijing Anzhen Hospital
Jan 16, 2023
Adverse Effect of Cardiovascular Medications (Diagnosis) Trial in Zibo (Evolocumab combined with statins, Statin)
Recruiting
- Adverse Effect of Cardiovascular Medications (Diagnosis)
- Evolocumab combined with statins
- Statin
-
Zibo, Shandong, ChinaZibo Central Hospital
Mar 24, 2023
Sudden Sensorineural Hearing Loss Trial (Statin, methylprednisolone, dexamethasone)
Not yet recruiting
- Sudden Sensorineural Hearing Loss
- Statin
- +3 more
- (no location specified)
Feb 2, 2023
Drug Adherence Trial (Red yeast rice extract initial therapy followed later on by statin therapy, Statin therapy)
Not yet recruiting
- Moderate 10-year Atherosclerotic Cardiovascular Disease Risk Patients
- Red yeast rice extract initial therapy followed later on by statin therapy
- Statin therapy
- (no location specified)
Apr 26, 2023
HMG-CoA Reductase Inhibitors on Meibomian Gland Morphology in
Completed
- Meibomian Gland Dysfunction
- +2 more
- Keratograph 5M, Oculus, Wetzlar, Germany
-
Taipei, TaiwanNational Taiwan University Hospital
Oct 12, 2020
Coronary Artery Diseasse Trial in Seoul (fixed high potent statin therapy, targeted LDL-C goal statin)
Active, not recruiting
- Coronary Artery Diseasse
- fixed high potent statin therapy
- targeted LDL-C goal statin
-
Seoul, Korea, Republic ofDivision of Cardiology, Department of Internal Medicine, Yonsei
Jul 19, 2022
Diabetes, Pre Diabetes, ASCVD Trial (high-intensity statin arm, low-intensity statin plus ezetimibe)
Not yet recruiting
- Diabetes Mellitus
- +2 more
- high-intensity statin arm
- low-intensity statin plus ezetimibe
- (no location specified)
Oct 12, 2022
Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation Trial in Seoul
Not yet recruiting
- Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation
- ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)
- high-intensity statin monotherapy (atoravastatin 40mg)
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Mar 21, 2023
Acute Coronary Syndrome, Hyperlipidemias, Percutaneous Coronary Intervention Trial in Nanjing (Placebo plus high-intensity
Not yet recruiting
- Acute Coronary Syndrome
- +3 more
- Placebo plus high-intensity statin
- PCSK 9 Inhibitor plus high-intensity statin
-
Nanjing, Jiangsu, ChinaNanjing First Hospital
Aug 1, 2022
Prognosis of Ischemic Stroke Due to Large-artery Atherosclerosis
Recruiting
- Ischemic Stroke
- Large-Artery Atherosclerosis (Embolus/Thrombosis)
- carotid artery stenting
- +6 more
-
Wuhan, ChinaTongji Hospital, Tongji Medical College, Huazhong University of
Oct 31, 2022
Coronary Artery Calcification, Metabolic Syndrome, Dyslipidemias Trial (Guideline directed statin therapy, High intensity statin
Not yet recruiting
- Coronary Artery Calcification
- +2 more
- Guideline directed statin therapy
- High intensity statin plus ezetimibe therapy
- (no location specified)
Apr 25, 2023
Hypercholesterolemia Trial (Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin), Double Statin (simvastatin,
Completed
- Hypercholesterolemia
- Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)
- Double Statin (simvastatin, atorvastatin, or pravastatin)
- (no location specified)
Feb 7, 2022
DAPT and Statins on Clinical Outcomes in Percutaneous Coronary
Completed
- Platelet Aggregation Inhibitors
- +5 more
- DAPT, Statin
-
Seoul, Gang nam-Gu, Ilwon-Dong, Korea, Republic ofSamsung Medical Center
Dec 21, 2018
Strains, Acute Lymphoblastic Leukemia, Sepsis Trial in Mexico City (Simvastatin)
Recruiting
- Strains
- +2 more
-
Mexico City, MexicoHospital General de México "Dr. Eduardo Liceaga"
Jan 2, 2022